CPL'116双抑制JAK与ROCK治疗甲氨蝶呤应答不足的类风湿关节炎患者:一项随机、双盲、安慰剂对照2期试验
这项2期随机双盲安慰剂对照试验在波兰和乌克兰9家医院纳入106例甲氨蝶呤应答不足的活动性类风湿关节炎患者,口服CPL'116(60、120、240 mg)或安慰剂每日两次共12周;仅240 mg组第12周DAS28-CRP较基线的变化与安慰剂差异达统计学显著,药物总体耐受良好。
要点
- 240 mg每日两次组DAS28-CRP变化与安慰剂的差异为-0.89(95%CI -1.56至-0.22;p=0.010),仅该剂量达到主要终点。
- 60 mg与120 mg组差异分别为-0.15(95%CI -0.81至0.52;p=0.67)和-0.56(95%CI -1.25至0.12;p=0.10),均未达统计学显著。
- 未记录实验室或血液学异常,未见严重不良事件或死亡。
核心结论
- 作者认为CPL'116呈现剂量依赖性应答,240 mg每日两次高剂量具有显著疗效,药物总体耐受良好且与脂质异常或肌酸激酶升高无关;作者认为这些发现值得在更大规模研究和不同临床环境中进一步研究。
研究设计与样本
- 2期随机、双盲、剂量探索、安慰剂对照、平行组试验,在波兰和乌克兰9家医院或诊所纳入年龄18-75岁、确诊成人起病中重度类风湿关节炎至少6个月且当前甲氨蝶呤应答不足的患者。
- 106例患者经交互式网络应答系统按1:1:1:1随机(区组大小4,按年龄分层)接受口服CPL'116 60 mg、120 mg、240 mg或安慰剂每日两次共12周,并继续背景甲氨蝶呤。
- 主要终点为第12周DAS28-CRP较基线的变化,采用混合效应重复测量模型按改良意向性治疗分析,p值为名义值;安全性分析人群为至少接受一剂CPL'116或安慰剂的所有参与者。
主要发现
- 2022年5月30日至2024年2月7日共随机106例:CPL'116 60 mg组27例、120 mg组25例、240 mg组26例、安慰剂组28例;总体平均年龄54.4岁(SD 10.5),女性79例(75%)、男性27例(25%),所有个体自报为白人。
- 第12周DAS28-CRP较基线变化的最小二乘均值差异:60 mg组-0.15(95%CI -0.81至0.52;p=0.67),120 mg组-0.56(95%CI -1.25至0.12;p=0.10),240 mg组-0.89(95%CI -1.56至-0.22;p=0.010)。
- 2例发生严重治疗中出现的不良事件:60 mg组1例非致死性非ST段抬高型心肌梗死(判定可能与CPL'116相关),240 mg组1例非肌层浸润性膀胱癌(判定与CPL'116无关),两事件均导致停药。
- 240 mg组1例因白细胞减少停用CPL'116,判定可能与CPL'116相关;未报告严重不良事件或死亡。
- 任何CPL'116剂量均未记录实验室或血液学异常。
关键数值与推荐
- 主要终点达标情况:仅240 mg剂量组达到主要终点,其DAS28-CRP变化与安慰剂的差异为-0.89(95%CI -1.56至-0.22;p=0.010)。
- 60 mg组差异-0.15(95%CI -0.81至0.52;p=0.67)、120 mg组差异-0.56(95%CI -1.25至0.12;p=0.10)均未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在结论中提出这些发现值得在更大规模研究和不同临床环境中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Janus kinase (JAK) inhibitors are an effective treatment option in rheumatoid arthritis and other autoimmune diseases. However, the use of JAK inhibitors is associated with increased total cholesterol, LDL cholesterol, triglycerides, and creatinine kinase, reducing the net clinical benefit of using them. Adding Rho-associated protein kinase (ROCK) inhibition to JAK inhibition might provide cardioprotection as ROCK inhibitors have been shown to reduce vascular inflammation, improve endothelial function, and prevent cardiac remodelling in preclinical models. In this study we investigated CPL409116 (hereafter referred to as CPL'116), a novel dual JAK and ROCK inhibitor, in patients with rheumatoid arthritis with inadequate response to methotrexate, to assess dose-dependent effects on disease control, pharmacokinetics, and laboratory abnormalities among other safety events. METHODS: This phase 2, randomised, double-blind, dose-ranging, placebo-controlled, parallel group trial enrolled patients aged 18-75 years at nine hospitals or clinics in Poland and Ukraine. Main inclusion criteria were a documented diagnosis of adult-onset, moderate-to-severe rheumatoid arthritis for at least 6 months before screening, and inadequate response to current methotrexate treatment (oral or injected 15-25 mg once weekly, or ≥10 mg once weekly if reduced due to side-effects or intolerance). Participants were randomly assigned via an interactive web response system (1:1:1:1, block size of four, stratified by age) to oral CPL'116 (60 mg, 120 mg, or 240 mg) or placebo twice daily for 12 weeks, with continuation of background methotrexate. The primary endpoint of the study was the change from baseline in Disease Activity Score based on 28 joints and C-reactive protein (DAS28-CRP) at week 12, analysed with a mixed-effects repeated measures model by a modified intention-to-treat approach. p values were nominal. Safety parameters including adverse events, vital functions, and laboratory results were closely monitored and reported for the safety analysis population, comprising all participants who received at least one dose of CPL'116 or placebo. People with lived experience were not involved in the study. The trial was registered with ClinicalTrials.gov, NCT05374785, and is completed. FINDINGS: Between May 30, 2022, and Feb 7, 2024, 106 patients were randomly assigned (27 in the CPL'116 60 mg group, 25 in the 120 mg group, 26 in the 240 mg group, and 28 in the placebo group). Overall mean age was 54·4 years (SD 10·5); 79 (75%) of 106 participants were women and 27 (25%) were men, and all individuals self-reported as White. The least squares mean difference in the change from baseline in DAS28-CRP at 12 weeks with CPL'116 versus placebo was -0·15 (95% CI -0·81 to 0·52; p=0·67) for the 60 mg dose; -0·56 (-1·25 to 0·12; p=0·10) for the 120 mg dose; and -0·89 (-1·56 to -0·22; p=0·010) for the 240 mg dose. Thus the primary endpoint was met for the 240 mg dose only. Overall CPL'116 was well tolerated. Two participants had serious treatment-emergent adverse events (one in the 60 mg dose group [non-fatal non-ST-elevation myocardial infarction, deemed possibly related to CPL'116] and one in the 240 mg dose group [non-muscle invasive bladder cancer, deemed unrelated to CPL'116]); both events led to discontinuation of CPL'116. CPL'116 was also discontinued due to leukopenia which was deemed to be possibly related to CPL'116 in one participant who received the 240 mg dose. No severe adverse events or deaths were reported. No laboratory or haematology abnormalities were recorded at any CPL'116 dose. INTERPRETATION: The findings of this study suggest a dose-dependent response with CPL'116, with significant efficacy at the high dose of 240 mg twice daily. The drug was generally well tolerated and was not associated with lipid abnormalities or creatinine kinase increase. These findings warrant further investigation in larger studies and different clinical settings. FUNDING: Celon Pharma and the National Centre for Research and Development (Poland).
引用
- Wieczorek M, Kisiel B, Włodarczyk D, et al. Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2025. PMID: 40516565. doi:10.1016/S2665-9913(25)00060-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。